Arcadia Biosciences - RKDA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $3.25
  • Forecasted Upside: 828.57 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.35
▲ +0.01 (2.94%)

This chart shows the closing price for RKDA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Arcadia Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RKDA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RKDA

Analyst Price Target is $3.25
▲ +828.57% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Arcadia Biosciences in the last 3 months. The average price target is $3.25, with a high forecast of $3.50 and a low forecast of $3.00. The average price target represents a 828.57% upside from the last price of $0.35.

This chart shows the closing price for RKDA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Arcadia Biosciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/15/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/13/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/12/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/12/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/10/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/8/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/7/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/7/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/26/2022HC WainwrightLower TargetBuy$4.00 ➝ $3.00Low
4/25/2022HC WainwrightLower Target$6.00 ➝ $4.00Low
3/31/2022Lake Street CapitalLower Target$4.50 ➝ $3.50Low
1/3/2022HC WainwrightLower TargetBuy$7.00 ➝ $6.00High
8/30/2021HC WainwrightReiterated RatingBuy$7.00Medium
6/1/2021HC WainwrightBoost TargetBuy$6.00 ➝ $7.00Medium
5/11/2021Lake Street CapitalInitiated CoverageBuy$4.50Medium
2/9/2021HC WainwrightLower TargetBuy$8.00 ➝ $6.00Low
12/28/2020HC WainwrightLower TargetBuy$10.00 ➝ $8.00N/A
11/30/2020HC WainwrightLower TargetBuy$12.00 ➝ $10.00Low
8/17/2020HC WainwrightLower TargetBuy$14.00 ➝ $12.00Low
5/26/2020National SecuritiesReiterated RatingBuy$16.00Medium
5/19/2020HC WainwrightReiterated RatingBuy$14.00Medium
3/26/2020National SecuritiesReiterated RatingBuy$16.00High
2/10/2020National SecuritiesReiterated RatingBuy$16.00Medium
12/23/2019HC WainwrightReiterated RatingBuy$14.00N/A
12/11/2019HC WainwrightReiterated RatingBuy$14.00Medium
12/2/2019HC WainwrightReiterated RatingBuy$14.00High
8/15/2019National SecuritiesBoost TargetBuy ➝ Buy$12.00 ➝ $20.00High
8/12/2019HC WainwrightReiterated RatingBuyHigh
6/6/2019HC WainwrightReiterated RatingBuy$20.00 ➝ $14.00Low
5/9/2019National SecuritiesReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00Low
4/17/2019National SecuritiesInitiated CoverageBuy$15.00Low
2/28/2019HC WainwrightReiterated RatingBuy$20.00High
12/13/2018HC WainwrightSet TargetBuy$20.00High
10/15/2018HC WainwrightSet TargetBuy$20.00High
8/8/2018HC WainwrightReiterated RatingBuy$20.00High
7/19/2018HC WainwrightSet TargetBuy$20.00High
6/19/2018HC WainwrightInitiated CoverageBuy$20.00Medium
3/14/2018Piper Jaffray CompaniesSet TargetHold$20.00High
(Data available from 12/7/2017 forward)

News Sentiment Rating

0.34 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/11/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/10/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/9/2022
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/8/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/8/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/7/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
12/7/2022

Current Sentiment

  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Arcadia Biosciences logo
Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring bath and body care. The company was incorporated in 2002 and is headquartered in Davis, California.
Read More

Today's Range

Now: $0.35
Low: $0.30
High: $0.35

50 Day Range

MA: $0.39
Low: $0.30
High: $0.57

52 Week Range

Now: $0.35
Low: $0.30
High: $2.66

Volume

115,593 shs

Average Volume

141,349 shs

Market Capitalization

$8.62 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.1

Frequently Asked Questions

What sell-side analysts currently cover shares of Arcadia Biosciences?

The following sell-side analysts have issued reports on Arcadia Biosciences in the last twelve months: HC Wainwright, Lake Street Capital, and StockNews.com.
View the latest analyst ratings for RKDA.

What is the current price target for Arcadia Biosciences?

2 Wall Street analysts have set twelve-month price targets for Arcadia Biosciences in the last year. Their average twelve-month price target is $3.25, suggesting a possible upside of 828.6%. Lake Street Capital has the highest price target set, predicting RKDA will reach $3.50 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $3.00 for Arcadia Biosciences in the next year.
View the latest price targets for RKDA.

What is the current consensus analyst rating for Arcadia Biosciences?

Arcadia Biosciences currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RKDA will outperform the market and that investors should add to their positions of Arcadia Biosciences.
View the latest ratings for RKDA.

What other companies compete with Arcadia Biosciences?

How do I contact Arcadia Biosciences' investor relations team?

Arcadia Biosciences' physical mailing address is 202 COUSTEAU PLACE SUITE 105, DAVIS CA, 85018. The basic materials company's listed phone number is (530) 756-7077 and its investor relations email address is [email protected] The official website for Arcadia Biosciences is www.arcadiabio.com. Learn More about contacing Arcadia Biosciences investor relations.